RxDoctor Payments Data

Gary Brotherson, MD

Ophthalmology · Erie, PANPI 1932173754

Payments from drug & device makers

$636in general payments, 2019–2025

Across 24 payments — averaging $26.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$182
  • Dompe US, Inc.$144
  • Apellis Pharmaceuticals, Inc.$107
  • Shire North American Group Inc$51
  • Amgen$39
  • Aerie Pharmaceuticals, Inc.$35
  • plus $78 from 5 others

What the payments were for

  • Food & beverage$59694%
  • Education$406%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$636 in reported general payments places this provider in the 35th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$236,001
Medicare patients
954
Services billed
3,232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost150$89,340
Travoprost56$15,037
RocklatanNetarsudil Mesylat/Latanoprost22$13,348
Latanoprost845$9,664
Timolol Maleate245$9,080
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol32$6,772
Alphagan PBrimonidine Tartrate21$5,337
Prednisolone Acetate202$5,119
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat233$5,107
SimbrinzaBrinzolamide/Brimonidine Tart13$4,828
VyzultaLatanoprostene Bunod14$3,526
Brimonidine Tartrate73$1,951
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha151$1,161
Dorzolamide Hcl45$403
MoxifloxacinMoxifloxacin Hcl17$277

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P$182$94,677171 claims
Aerie Pharmaceuticals, Inc.Rocklatan$35$13,34822 claims
AlconSimbrinza$18$4,82813 claims
Bausch & Lomb Americas Inc.Vyzulta$22$3,52614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Erie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →